Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The ...

With its multiple sclerosis powerhouse Ocrevus expected to lose patent protection by the end of the decade, Roche is looking for ways to extend the market exclusivity for the top-selling drug in ...

Ana de Armas and Keanu Reeves costarred in 2015's 'Knock Knock' before reuniting for the upcoming 'John Wick' spinoff ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The trial ...

The MUSETTE Phase 3 trial showed no added benefit of high-dose Ocrevus over the standard 600 mg IV dose in slowing disability progression. Ocrevus 600 mg IV maintained low disability progression ...

Investing.com -- Shares of Roche (SIX: RO, ROG; OTCQX: RHHBY (OTC:RHHBY)) declined by as much as 2.9% after the company announced that its Phase III MUSETTE trial of a higher dose of Ocrevus in ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 12, 2025 /EINPresswire / -- How Has the Ocrevus Market Grown Historically? .The Ocrevus market has experienced consistent expansion in recent years ...

Roche announced that the phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing ...